Dragonfly Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing multi-specific immune engagers and engineered cytokines that harness innate and adaptive immunity. The company advances programs across oncology, autoimmune and inflammatory diseases, fibrosis and neuro-inflammation, and conducts preclinical and early-phase clinical development while partnering and licensing programs to large pharmaceutical companies.
Industries
Nr. of Employees
medium (51-250)
Dragonfly Therapeutics, Inc.
Patents
Multi-specific binding proteins binding BCMA, NKG2D and CD16 and methods of use
US-12760105-B2
View DetailsMulti-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
US-12384851-B2
View DetailsCancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US-12384847-B2
View DetailsMethods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
US-12377144-B2
View DetailsMulti-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
US-12275791-B2
View Details
Multi-specific binding proteins binding BCMA, NKG2D and CD16 and methods of use
US-12760105-B2
View DetailsMulti-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
US-12384851-B2
View DetailsCancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US-12384847-B2
View DetailsMethods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
US-12377144-B2
View DetailsMulti-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
US-12275791-B2
View DetailsProducts
DF5112 (CCR6-targeting molecule)
A CCR6-targeting therapeutic designed to deplete Th17 cells and B cells; evaluated in a randomized, placebo-controlled Phase 1 study with IV and subcutaneous dosing cohorts to assess safety, PK, immunogenicity and pharmacodynamics.
DF1001 (HER2-targeted NK/T cell engager)
A HER2-targeted multi-specific engager that redirects NK and T cell activity to HER2-expressing tumors; progressed through Phase 1 and into Phase 2 for advanced solid tumors, with reported clinical responses and tolerability.
DF9001 (EGFR-targeted immune engager)
An investigational multi-specific engager that inhibits EGFR signaling while redirecting NK cells, gamma-delta T cells and CD8 T cells via activating receptors to induce anti-tumor immunity; evaluated in first-in-human Phase 1/2 studies.
DF6215 (engineered IL-2 cytokine)
A modified, half-life–extended IL-2 designed to bias activation toward anti-tumor CD8 T cells and NK cells while minimizing regulatory T cell expansion and systemic toxicity; evaluated preclinically and in a Phase 1/1b clinical trial in advanced solid tumors.
DF6002 (IL-12 cytokine program)
An IL-12–based cytokine program (extended half-life IL-12 Fc format) developed to modulate tumor microenvironment and boost innate and adaptive anti-tumor responses; referenced as a partnered/licensed program.
DF5112 (CCR6-targeting molecule)
A CCR6-targeting therapeutic designed to deplete Th17 cells and B cells; evaluated in a randomized, placebo-controlled Phase 1 study with IV and subcutaneous dosing cohorts to assess safety, PK, immunogenicity and pharmacodynamics.
DF1001 (HER2-targeted NK/T cell engager)
A HER2-targeted multi-specific engager that redirects NK and T cell activity to HER2-expressing tumors; progressed through Phase 1 and into Phase 2 for advanced solid tumors, with reported clinical responses and tolerability.
DF9001 (EGFR-targeted immune engager)
An investigational multi-specific engager that inhibits EGFR signaling while redirecting NK cells, gamma-delta T cells and CD8 T cells via activating receptors to induce anti-tumor immunity; evaluated in first-in-human Phase 1/2 studies.
DF6215 (engineered IL-2 cytokine)
A modified, half-life–extended IL-2 designed to bias activation toward anti-tumor CD8 T cells and NK cells while minimizing regulatory T cell expansion and systemic toxicity; evaluated preclinically and in a Phase 1/1b clinical trial in advanced solid tumors.
DF6002 (IL-12 cytokine program)
An IL-12–based cytokine program (extended half-life IL-12 Fc format) developed to modulate tumor microenvironment and boost innate and adaptive anti-tumor responses; referenced as a partnered/licensed program.
Expertise Areas
- Multi-specific immune cell engager discovery
- Engineered cytokine development
- Early-phase clinical development and combination studies
- Immuno-oncology and tumor immunology
Key Technologies
- Multi-specific immune cell engagers
- Engineered cytokines (IL-2, IL-12 formats)
- Bispecific/tri-specific antibody constructs
- NK cell receptor engagement
News & Updates
First healthy volunteers successfully dosed subcutaneously; IV cohort showed strong depletion of Th17 and B cells. Phase 1 is a randomized, placebo-controlled study evaluating safety, PK, immunogenicity and pharmacodynamics.
Poster presentations showed DF6215 drives preferential effector expansion and synergy with PD-1 blockade without added toxicity; DF9001 showed EGFR signal inhibition plus immune-mediated efficacy and favorable safety in GLP NHP studies.
Announcement of a clinical collaboration to evaluate the EGFR-targeted engager in combination with a PD-1 checkpoint inhibitor in patients with solid tumors.
Lead HER2-targeted NK cell engager received orphan drug designation for treatment of esophageal cancer; ongoing Phase 1/2 clinical trial with no DLTs reported in early cohorts.
Expansion of a multi-target research collaboration to discover and develop immunotherapies for autoimmune and fibrotic disease targets with option-to-license terms and milestone/royalty economics.
Report of an exclusive-option licensing agreement with a pharmaceutical company for multiple solid-tumor programs leveraging the company's multi-specific NK engager technology, with substantial potential milestone payments.
First healthy volunteers successfully dosed subcutaneously; IV cohort showed strong depletion of Th17 and B cells. Phase 1 is a randomized, placebo-controlled study evaluating safety, PK, immunogenicity and pharmacodynamics.
Poster presentations showed DF6215 drives preferential effector expansion and synergy with PD-1 blockade without added toxicity; DF9001 showed EGFR signal inhibition plus immune-mediated efficacy and favorable safety in GLP NHP studies.
Announcement of a clinical collaboration to evaluate the EGFR-targeted engager in combination with a PD-1 checkpoint inhibitor in patients with solid tumors.
Lead HER2-targeted NK cell engager received orphan drug designation for treatment of esophageal cancer; ongoing Phase 1/2 clinical trial with no DLTs reported in early cohorts.
Expansion of a multi-target research collaboration to discover and develop immunotherapies for autoimmune and fibrotic disease targets with option-to-license terms and milestone/royalty economics.
Report of an exclusive-option licensing agreement with a pharmaceutical company for multiple solid-tumor programs leveraging the company's multi-specific NK engager technology, with substantial potential milestone payments.